Evaluation of acute intestinal toxicity in relation to the volume of irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for locally advanced pancreatic cancer.
Yoshinori Ito(National Cancer Center Hospital East), Hiroshi Ikeda, Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Hideki Ueno(National Defense Medical College), Takuji Okusaka(National Cancer Centre Japan), Atsushi Imai(Tokyo Metropolitan Matsuzawa Hospital), Yoshikazu Kagami(Tokyo National Hospital), Naoko Fujimoto(Tokyo National Hospital), Masafumi Ikeda(National Cancer Center Hospital East)
PubMed
December 5, 2006
Cited by 19
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
|British Journal of Cancer|2010|749